These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 25505208)

  • 1. Thyroid carcinoma, version 2.2014.
    Tuttle RM; Haddad RI; Ball DW; Byrd D; Dickson P; Duh QY; Ehya H; Haymart M; Hoh C; Hunt JP; Iagaru A; Kandeel F; Kopp P; Lamonica DM; Lydiatt WM; McCaffrey J; Moley JF; Parks L; Raeburn CD; Ridge JA; Ringel MD; Scheri RP; Shah JP; Sherman SI; Sturgeon C; Waguespack SG; Wang TN; Wirth LJ; Hoffmann KG; Hughes M
    J Natl Compr Canc Netw; 2014 Dec; 12(12):1671-80; quiz 1680. PubMed ID: 25505208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
    Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
    de Castroneves LA; Negrão MV; de Freitas RM; Papadia C; Lima JV; Fukushima JT; Simão EF; Kulcsar MA; Tavares MR; Jorge AA; de Castro G; Hoff PM; Hoff AO
    Thyroid; 2016 Mar; 26(3):414-9. PubMed ID: 26701095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The evolving field of kinase inhibitors in thyroid cancer.
    Marotta V; Sciammarella C; Vitale M; Colao A; Faggiano A
    Crit Rev Oncol Hematol; 2015 Jan; 93(1):60-73. PubMed ID: 25240824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
    Massicotte MH; Brassard M; Claude-Desroches M; Borget I; Bonichon F; Giraudet AL; Do Cao C; Chougnet CN; Leboulleux S; Baudin E; Schlumberger M; de la Fouchardière C
    Eur J Endocrinol; 2014 Apr; 170(4):575-82. PubMed ID: 24424318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.
    Ruan M; Liu M; Dong Q; Chen L
    J Clin Endocrinol Metab; 2015 May; 100(5):1771-9. PubMed ID: 25768669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib.
    Dadu R; Devine C; Hernandez M; Waguespack SG; Busaidy NL; Hu MI; Jimenez C; Habra MA; Sellin RV; Ying AK; Cote GJ; Sherman SI; Cabanillas ME
    J Clin Endocrinol Metab; 2014 Jun; 99(6):2086-94. PubMed ID: 24628550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer.
    Takami HE
    Endocr J; 2011; 58(3):151-3. PubMed ID: 21383525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer.
    Fagin JA; Tuttle RM; Pfister DG
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2621-4. PubMed ID: 20525911
    [No Abstract]   [Full Text] [Related]  

  • 10. Sorafenib in the treatment of thyroid cancer.
    Ferrari SM; Politti U; Spisni R; Materazzi G; Baldini E; Ulisse S; Miccoli P; Antonelli A; Fallahi P
    Expert Rev Anticancer Ther; 2015; 15(8):863-74. PubMed ID: 26152651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic management of metastatic medullary thyroid carcinoma: role of new tyrosine kinase inhibitors.
    García-Martín A; López-Ibarra Lozano PJ; Triviño-Ibáñez EM; Escobar-Jiménez F
    Endocrinol Nutr; 2013 Mar; 60(3):152-3. PubMed ID: 22565118
    [No Abstract]   [Full Text] [Related]  

  • 12. Sorafenib and thyroid cancer.
    Fallahi P; Ferrari SM; Santini F; Corrado A; Materazzi G; Ulisse S; Miccoli P; Antonelli A
    BioDrugs; 2013 Dec; 27(6):615-28. PubMed ID: 23818056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of advanced thyroid cancer: role of molecularly targeted therapies.
    Covell LL; Ganti AK
    Target Oncol; 2015 Sep; 10(3):311-24. PubMed ID: 26335853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib: 10 years after the first pivotal trial.
    Gadaleta-Caldarola G; Infusino S; Divella R; Ferraro E; Mazzocca A; De Rose F; Filippelli G; Abbate I; Brandi M
    Future Oncol; 2015; 11(13):1863-80. PubMed ID: 26161924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.
    Worden F; Fassnacht M; Shi Y; Hadjieva T; Bonichon F; Gao M; Fugazzola L; Ando Y; Hasegawa Y; Park DJ; Shong YK; Smit JW; Chung J; Kappeler C; Meinhardt G; Schlumberger M; Brose MS
    Endocr Relat Cancer; 2015 Dec; 22(6):877-87. PubMed ID: 26370187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib in metastatic thyroid cancer: a systematic review.
    Thomas L; Lai SY; Dong W; Feng L; Dadu R; Regone RM; Cabanillas ME
    Oncologist; 2014 Mar; 19(3):251-8. PubMed ID: 24563075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Off-label use of Sorafenib in patients with advanced thyroid carcinoma: Retrospective analysis of five cases.
    Bugalho MJ
    J Cancer Res Ther; 2016; 12(2):1084-7. PubMed ID: 27461704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timing of multikinase inhibitor initiation in differentiated thyroid cancer.
    Brose MS; Smit J; Lin CC; Pitoia F; Fellous M; DeSanctis Y; Schlumberger M; Tori M; Sugitani I
    Endocr Relat Cancer; 2017 May; 24(5):237-242. PubMed ID: 28270435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib.
    Kawalec P; Malinowska-Lipień I; Brzostek T; Kózka M
    Expert Rev Anticancer Ther; 2016 Dec; 16(12):1303-1309. PubMed ID: 27734713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
    Cabanillas ME; Waguespack SG; Bronstein Y; Williams MD; Feng L; Hernandez M; Lopez A; Sherman SI; Busaidy NL
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2588-95. PubMed ID: 20392874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.